Arterial Thrombotic Complications of Tyrosine Kinase Inhibitors

Area of Science:

• Oncology
• Pharmacology
• Cardiovascular Medicine

Background:

• Kinase dysregulation is implicated in various hematologic and solid malignancies.
• Tyrosine kinases (TKs) are crucial in tumor progression, metastasis, and immune evasion.
• Tyrosine kinase inhibitors (TKIs) have revolutionized cancer therapy, demonstrating significant efficacy.

Purpose of the Study:

• To review the clinical scope of arterial thrombotic complications associated with TKIs.
• To focus on TKIs targeting the BCR-ABL1 translocation, commonly used in certain leukemias.
• To discuss potential mechanisms underlying TKI-induced prothrombotic events.

Main Methods:

• Review of clinical experience with commonly used TKIs.
• Focus on TKIs targeting BCR-ABL1, VEGF, and PDGF receptors.
• Discussion of proposed mechanisms for arterial thrombotic complications.

Main Results:

• Certain TKIs, while effective, are linked to increased rates of vascular events, including myocardial infarction and stroke.
• Prothrombotic complications are a presumed mechanism for these adverse vascular events.
• TKIs targeting BCR-ABL1 are highlighted in the context of these complications.

Conclusions:

• TKIs offer significant therapeutic benefits but carry risks of serious arterial thrombotic events.
• Understanding the mechanisms of these complications is crucial for developing safer TKI therapies.
• Future strategies may involve unique TKI targeting or mitigation approaches to reduce adverse events without compromising efficacy.